• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Regeneron posts mixed Q1 results, Eylea growth slows

May 4, 2017 By Sarah Faulkner

RegeneronShares in Regeneron (NSDQ:REGN) rose today after the company beat revenue expectations on The Street with its 1st quarter financial results.

The company’s total sales rose to $1.32 billion, exceeding analysts’ estimate of $1.30 billion. Regeneron’s bottom line jumped 37% to $248.9 million.

Adjusted to exclude 1-time items, earnings per share were $2.92, which missed analysts’ estimate by 14¢. The company cited a larger-than-expected tax bill as the root cause of its missed earnings.

REGN shares jumped more than 6% to 434.12 apiece today in mid-afternoon activity.

In a post-earnings call, CEO Leonard Schliefer reportedly said that its eczema drug Dupixent was off to a strong start and that 3,500 prescriptions for it have been written since it was approved in late March.

Jefferies analyst Biren Amin lifted his estimate for Dupixent’s 2017 sales to $144 million after learning that the number of prescriptions was significantly higher than the 2,500 prescriptions partner Sanofi reported last week.

Regeneron added that 2 large U.S. pharmacy benefit managers have agreed to cover Dupixent. The drug costs $37,000 and is expected to bring in peak annual sales of more than $4 billion, according to Reuters. 

The company is hoping that 2 of its therapies, sarilumab and Dupixent, will reduce its reliance on Eylea, which has fueled much of the company’s growth since 2011. Eylea accounts for almost 70% of Regeneron’s total revenue.

The drug’s sales have slowed in recent years, thanks to competition from Roche’s Lucentis. Sales of Eylea in the U.S. climbed 9% to $854 million in the 1st quarter of this year, just missing analysts’ estimates.

Material from Reuters was used in this report. 

Filed Under: Featured, MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Regeneron

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS